Observational Study on the Safety and Effectiveness of Guselkumab After Switching from Ustekinumab in Moderate to Severe Psoriasis Patients in Routine Clinical Practice

What This Trial Is About

Researchers are assessing how well Guselkumab works in people with moderate to severe psoriasis who switch from Ustekinumab in everyday medical practice. Psoriasis is a long-lasting skin condition that causes red, scaly, and sometimes painful or itchy patches on the skin. This observational study collects information from routine clinical care without providing study drugs. Participants are people with moderate to severe plaque psoriasis who are candidates for systemic treatment and are medically advised to switch from Ustekinumab or its biosimilar to Guselkumab. No medications are given by the study instead, data about the switch and treatment outcomes are gathered from regular medical visits. The study will monitor participants over time to observe treatment effects in a real-world setting. During the study, data from participants routine clinical visits will be collected, including skin assessments, quality of life questionnaires, and physician evaluations at various time points up to one year. Researchers will measure skin severity scores, body surface area affected, and quality of life indexes. Safety information and reasons for treatment changes will also be tracked. Participation involves no additional treatments beyond usual care, and the study lasts up to 52 weeks following the switch to Guselkumab.

A Study of Guselkumab Given After Ustekinumab in Participants With Moderate to Severe Psoriasis in Routine Clinical Practice